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Background: The role of angiogenesis in the pathogenesis of pleural effusion (PE) has not
been determined. The expression of angiogenic factors may represent useful markers for
the diagnosis and prediction of disease outcome. To measure the pleural fluid (PF) and
serum levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor
(bFGF) and Tie receptor tyrosine kinase (Tie-2) in order to investigate their role in the
pathogenesis of PEs.
Methods: Sixty-seven, 17 with transudative PEs due to heart failure and 50 with exudative
PEs (malignant, 22; inflammatory, 15; undiagnosed, 13) were included in the study. PF and
serum levels of the growth factors (VEGF, bFGF and Tie-2) were measured using enzyme-
linked immunosorbent assays.
Results: PF and serum VEGF levels but not bFGF and Tie-2 levels were higher (po0.005) in
exudates than in transudates. PF VEGF levels were significantly higher in malignant than
inflammatory and undiagnosed PEs (p ¼ 0.03). In addition, PF Tie-2 levels were not found
different in malignant or in parapneumonic PEs.
Conclusion: Our results showed that VEGF is one of the main mediators in exudative PEs,
but this effect is not mediated through the angiogenetic pathway Ang-1/Tie-2. However,
the role of angiogenesis and its pathways in the pathogenesis of exudative PEs needs
further exploration.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
1; Ang-2, angiopoietin 2; bFGF, basic fibroplast growth factor; IQR, interquartile range, PE, pleural
e dehydrogenase, Tie-2, tie receptor tyrosine kinase, VEGF, vascular endothelial growth factor.
(N.M. Siafakas).
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Pleural effusion (PE) is common finding in clinical practice.
Increased vascular permeability and leakage play a principal
role in the development of exudative PEs.1 However, the
role of angiogenesis in the pathogenesis of PE has not been
determined. Angiogenesis is controlled by a balance of
positive and negative regulators involved in multiple path-
ways that result in endothelial cell proliferation, differ-
entiation and organization into a functional network of
vascular channels.2,3 These regulatory factors have a potent
angiogenic effect, and their precise coordination is essential
for vascular development. Angiogenic cytokines, such as
vascular endothelial growth factor (VEGF) and basic fibro-
blast growth factor (bFGF) are candidates for the induction
of PEs because they have been implicated in the induction of
neovascularization, vascular permeability, and hemorrhage
both in the inflammatory process and in tumor progres-
sion.2–7 Thus, the expression of angiogenic factors may
represent useful markers for diagnosis and prediction of
disease outcome.
VEGF has been reported to play an important role in the
development of certain types of effusion.6,8–11 Several
studies indicate that VEGF is consistently higher in exuda-
tive than in transudative PEs.12–14 Effusions associated with
malignancies seem to have higher levels of VEGF than benign
effusions.8,9,13,15,17–19 It has been suggested that increased
VEGF levels in the malignant PEs increase vascular perme-
ability and contribute to fluid accumulation.9,16 Despite
the statistically significant differences in pleural fluid (PF)
VEGF levels between malignant and non-malignant effu-
sions, substantial overlap exists, suggesting that VEGF
levels are unlikely to be useful diagnostically as a single
marker.20
Recently, another endothelial cell-specific receptor tyr-
osine kinase (Tie-2) and its ligand family, angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2), have been shown to
mediate different functions of angiogenesis.20–23 Identified
on the basis of homology screening, Ang-2 acts as an
alternative ligand for Tie-220,21 and binds to Tie-2 with
similar affinity, but competitively antagonizes Ang-1 effects
with blockage of Tie-2 phosphorylation and activation.
Functionally, transgenic mice over-expressing Ang-2 show
similar defects as the Ang-1 or Tie-2 deficient mice,
suggesting that Ang-2 acts as a natural antagonist to Ang-
1/Tie-2 action.20–23 In line with this notion, it has been
recently reported that Ang-2 levels but not Ang-1 levels are
elevated in exudative PEs suggesting that Ang-2 along with
VEFG participate in pleural inflammation and the pathogen-
esis of exudative PEs.17 On the contrary, it was suggested
that Ang-2 may have a direct role in stimulating Tie-2
receptor signaling and inducing in vitro angiogenesis.24
These findings indicate that the physiological role of Ang-2
is more complex than previously recognized: acting alter-
nately to promote or blunt Tie-2 receptor signaling in
endothelial cells, depending on local conditions.24
To the best of our knowledge, the role of Tie-2 in the
pathogenesis of PEs has not been investigated. The aim of
the present study was to determine the levels of VEGF, bFGF,
and Tie-2 in PF and corresponding serum samples of patients
with PEs, in order to further evaluate the signaling pathway
of VEGF through the angiopoietins’ receptor, Tie-2. Ourresults indicate that VEGF does not act through the Tie-2
receptor pathway in exudative PEs.
Methods and materials
Between January 1, 2004 and August 30, 2005, we
prospectively studied 67 consecutive patients with PEs.
The study was approved by the Ethics Committee of our
hospital, and before the thoracentesis all patients signed an
informed consent.
PEs were categorized as exudates or transudates accord-
ing to Light’s criteria.25–27 A PE was attributed to heart
failure when it was transudative, the patient had symptoms
and signs of left ventricular failure, a heart ultrasound study
revealed systolic or diastolic dysfunction of the left
ventricle, and the PE responded to the appropriate therapy.
A malignant PE was diagnosed if the PF cytology or pleural
biopsy findings were positive for malignant cells, (i.e.,
proven malignant PE), or if the patient had a persistent PE
with a known malignancy and alternative diagnoses were
excluded (i.e., probable malignant PE). A parapneumonic PE
was defined as one associated with bacterial pneumonia,
including empyema. A PE was categorized as tuberculous if
Mycobacteria tuberculosis were found in PF, sputum,
bronchial lavage fluid, or pleural biopsy specimen (positive
smear or culture) [i.e., proven tuberculous PE] or if pleural
biopsy revealed granuloma and other granulomatous dis-
eases were excluded (i.e., probable tuberculous PE). A
specific diagnosis could not be made even after open pleural
biopsy, and they were included in the ‘‘undiagnosed’’ group.
The PF was aspirated and blood was drawn immediately
after the thoracentesis, and the specimens were collected
in plain sterile tubes. PF and blood samples were centri-
fuged at 1000g at 4 1C for 10min. PF supernatants and serum
samples were stored at 80 1C. The following characteristics
were recorded: PF and serum total protein levels; lactate
dehydrogenase (LDH) concentration (upper limit for serum
LDH, 480 IU/L); glucose levels; PF pH; PF nucleated cell
counts; and differential cell counts.
The levels of VEGF, bFGF Tie-2 in PE and serum were
measured by enzyme-linked immunosorbent assay using a
duoset methodology (R&D Systems; Minneapolis, MN).
Briefly, after standard procedures, the cell-free samples
were pipetted into the wells of the microtitre plates,
specific horseradish peroxidase-linked polyclonal antibodies
were added and immunoreactive levels of VEGF, bFGF and
Tie-2 were determined. Values below the detection limit
were assumed as zero.
Statistical analysis
Values were reported as the median (interquartile range
[IQR]) for non-normally and as mean (SD) for normally
distributed variables. Mann–Whitney, Kruskal–Wallis, and
Wilcoxon ranked sum tests were used to assess the
difference between different groups, as appropriate. The
Spearman test was used to assess the correlation between
variables. Values below the detection limit were assumed to
be zero for statistical analysis. For statistical analysis, a
statistical software package SPSS, version 11.0; SPSS Inc.,
Chicago, IL was used.
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Table 2 Pleural fluid and serum VEGF in patients with
PEs of different etiologies.
VEGF levels
(pg/mL)
Variables PF Serum p-Valuey
Malignancy 657
(116–4870)
571
(121–13 575)
NS
Inflammatory 590
(66–4560)
1114
(125–9759)
NS
Undiagnosed
exudates
116
(36–2714)
527
(81–2944)
NS
p-Valuez 0.03 NS
NS ¼ non-significant.
Values are given as the median (IQR).
yCorresponds to the difference in PF and serum levels of
VEGF.
zCorresponds to the differences among patients with PEs of
various etiologies (Kruskal–Wallis test).
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Patient characteristics
Sixty-seven patients, 41 men and 26 women were included
in the study. The median age was 73.5 years (IQR, 20–95
years). Seventeen patients had transudative PEs due to
heart failure, and 50 patients had exudative PEs of different
origin: malignant PEs, 22 (lung cancer, 12; metastatic
malignancies, 10); inflammatory PEs, 15 (12 parapneumonic,
tuberculous PEs, 3); and pleural exudates remained un-
diagnosed, 13. The PF and serum concentrations of VEGF,
bFGF and Tie-2, were measured in 66, 66, and 62 patients,
respectively.
VEGF levels in patients with PEs
PF and serum VEGF levels were higher in exudates (po0.001
and po0.05, respectively) than in transudates (Table 1).
No significant differences were detected between inflam-
matory and malignant VEGF levels, in both serum and
PF. In transudates, the PF VEGF levels were significantly
decreased in comparison with serum levels (p ¼ 0.02)
(Table 1). PF VEGF levels were significantly higher in
malignant than inflammatory and undiagnosed PEs (p ¼
0.03) (Table 2). VEGF ratio (pleural/serum) statistically
significantly related with LDH ratio (r ¼ 0.449, p ¼ 0.0001)
(Figure 1) and Total Protein ratio (r ¼ 0.361, p ¼ 0.003)
(Figure 2).
bFGF levels in patients with PEs
PF and serum bFGF levels were not different (p40.05) in
exudates than in transudates (Table 1). In exudates, the PF
bFGF levels were significantly increased in comparison with
serum levels (po0.0001) (Table 1). No significant differ-
ences were detected between inflammatory and malignant
bFGF levels, in both serum and PF. PF and serum bFGF levels
were not significantly different in the various types ofTable 1 Pleural fluid and serum levels in patients with pleura
Variables Exudates
VEGF pg/mL PF 534 (36–4867)
Serum 616 (81–13 575)
pz NS
bFGF pg/mL PF 3.8 (1.9–16.4)
Serum 2.1(0.2–16.6)
pz po0.0001
Tie-2 pg/mL PF 0.6 (0.2–3.6)
Serum 1 (0.1–30.5)
pz NS
NS ¼ non-significant.
Values are given as the median (IQR).
yCorresponds to the difference in PF or serum levels between exu
zCorresponds to the difference between PF and serum levels of aexudates (malignant, inflammatory, and undiagnosed PEs;
Table 3). No significant correlation was found between bFGF
levels and chemical (LDH ratio, total protein ratio)
parameters.Tie-2 levels in patients with PEs
PF and serum Tie-2 levels were not different (p40.05) in
exudates than in transudates (Table 1). In both exudates and
transudates PF, Tie-2 levels were not significantly different
in comparison with serum levels (p40.05) (Table 1). PF
and serum Tie-2 levels were not significantly different in
the different exudates (malignant, inflammatory, and
undiagnosed PEs) (Table 4). No significant correlation was
found between Tie-2 levels and chemical or hematologic
parameters.l exudate and pleural transudate.
Transudates py
86 (25–4867) o0.001
285 (10 592.63–60.1) o0.05
p ¼ 0.02
3.1 (1.7–7.7) NS
1.9 (4.3–0.3) NS
p ¼ 0.06
0.5 (0.2–4.1) NS
0.3 (0.2–5.4) NS
NS
dates and transudates.
growth factor.
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Figure 2 Relationship between PF/serum VEGF ratio and
PF/serum total protein ratio.
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Figure 1 Relationship between PF/serum VEGF ratio and
PF/serum LDH ratio.
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To the best of our knowledge, this is the first report on PF
levels of Tie-2. Our main findings were as follows: (1) PF
VEGF levels, but not bFGF and Tie-2 levels were significantly
elevated in pleural exudates than in transudates; (2) PF Tie-
2 levels were not different between malignant and
inflammatory PE, nor when compared with transudates;
and (3) VEGF ratio was found to correlate with LDH ratio and
total protein ratio.
This study confirms that VEGF, which has potent angio-
genic, mitogenic, and vascular permeability-enhancing
properties, could be implicated in the pathogenesis of
exudative PEs of different origin. In agreement with datareported in previous studies,12–14,17 we have found VEGF
levels significantly higher in exudates than in transudates.
Recent studies have demonstrated high levels of VEGF in
exudative inflammatory and neoplastic PEs, and a possible
aetiological role in the pathogenesis of these types of
effusions.12,15,28 We have also found the highest VEGF levels
in malignant than parapneumonic PEs. In addition, VEGF
levels were correlated with markers of increased vascular
permeability and pleural inflammation, such as LDH ratio
and protein ratio, in alignment with a recent study.17
The novel finding of this study is that Tie-2 levels in both
PF and systemic circulation was not found to differentiate
between transudates and exudates. This finding, supports
the recent report showed that Ang-2 levels but not Ang-1
levels were found elevated in exudative PEs.17 Angiogenesis
is a very complicated network which is closely regulated by
many angiogenic factors. VEGF and angiopoietins are the
two most important regulators. Ang-1 and Ang-2 have been
reported as the most potent regulators for neovasculariza-
tion and are the activator and antagonist of Tie-2 receptor.
The binding of Ang-1 causes autophosphorylation of Tie-2
while the Ang-2 binding suppresses the autophosphoryla-
tion.20–22,29 Although, the exact role of angiopoietin/Tie-2
system remains enigmatic, there is evidence that this
system in the presence of VEGF is important for the
initiation of angiogenesis and vascular sprouting in tu-
mors.2,3,8,9,29 In support of this, it has been reported that
VEGF and angiopoietin/Tie-2 system play a key role in the
transformation of normal lung to non-small cell lung
carcinoma.30–32 These results indicate that expression of
the angiopoietin/Tie-2 pathway is not uniform amongst
normal human tissues and tumor tissues in the different
studies.30–32 On the other hand, using immunohistochemical
detection, Peters et al.33 reported an increased proportion
of Tie-2-expresssing tumor vessels in breast carcinomas. The
balance between VEGF and angiopoietins/Tie-2 pathway has
been also investigated in other systems, with different and
not conclusive results.24,33–35 These differences could be
related to a variety of methods that have been used. In
our study, we did not find a differential role for the mole-
cule of Tie-levels in the different PEs. This finding may
indicate that Tie-2 does not operate along with VEGF in
pleural inflammation and the formation of exudative PEs
exudations.
In addition, in the present study, we did not find
differences between bFGF levels in exudates and transu-
dates. Two recent studies reported controversial results as
far the bFGF levels in PEs is concerned.7,36 The most recent
report showed reduced protein expression of bFGF and IL-8,
two potent angiogenic factors, in PEs from breast cancer,
with conserved expression of VEGF.36 The results of our
study are in agreement with this study.36
In conclusion, this study confirms that VEGF is up-
regulated in exudative PEs of different origin. On the other
hand, we have found that this pathogenetic effect is rather
not mediated through the pathway of angiopoietins/Tie-2,
as we did not detect any difference of Tie-2 levels in PEs.
However, the measurements of PF levels of the examined
angiogenic mediators could not be used for diagnostic
purposes. In contrast, we could suggest that our data hold
some, however, immature, pathogenetic, and therapeutic
implications. Our next step would be to verify this first
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Table 3 Pleural fluid and serum bFGF in patients with PEs of different etiologies.
bFGF Levels (pg/mL)
Variables PF Serum p-Valuey
Malignancy 4.8210 (1640–1.94) 1.626 (16.6–0.2) o0.05
Inflammatory 4.8920 (13.87–2.18) 3.137 (5.5–0.9) o0.05
Undiagnosed exudates 3.1280 (8.91–1.89) 1.716 (7.5–0.6) o0.05
p-Valuez NS NS
NS ¼ non-significant.
Values are given as the median (IQR), unless otherwise indicated.
yCorresponds to the difference in PF and serum levels of FGF.
zCorresponds to the differences among patients with PEs of various etiologies (Kruskal–Wallis test).
Table 4 Pleural fluid and serum Tie-2 in patients with PEs of different etiologies.
Tie-2 levels pg/mL
Variables PF Serum p-Valuey
Malignancy 0.74 (0.2–3.5) 0.44 (0.1–7.5) NS
Inflammatory 0.58 (0.3–1.7) 1.42 (0.2–4.8) NS
Undiagnosed exudates 0.46 (0.3–1.4) 0.49 (0.1–30.5) NS
p-Valuez NS NS
NS ¼ non-significant.
Values are given as the median (IQR), unless otherwise indicated.
yCorresponds to the difference in PF and serum levels of Tie-2.
zCorresponds to the differences among patients with PEs of various etiologies (Kruskal–Wallis test).
F. Economidou et al.778observation by using more quantitative methods such as
reverse transcription-polymerase chain reaction (Real time
RT-PCR) and in situ hybridization (ISH). Finally, our results
suggest that VEGF may have a significant role in the
pathogenesis of exudation in the pleural cavity, possibly
via not only by its angiogenetic function but as an inducer of
vascular permeability as well.
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